Johnson & Johnson (FRA:JNJ)
Germany
· Delayed Price · Currency is EUR | Market Cap | 325.67B |
| Revenue (ttm) | 82.47B |
| Net Income (ttm) | 20.13B |
| Shares Out | n/a |
| EPS (ttm) | 8.29 |
| PE Ratio | 16.17 |
| Forward PE | 14.78 |
| Dividend | 4.62 (3.39%) |
| Ex-Dividend Date | May 27, 2025 |
| Volume | 1,090 |
| Average Volume | 3,428 |
| Open | 136.38 |
| Previous Close | 136.16 |
| Day's Range | 135.58 - 136.50 |
| 52-Week Range | 128.16 - 161.30 |
| Beta | n/a |
| RSI | 48.54 |
| Earnings Date | Jul 16, 2025 |
About Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of various products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizo... [Read more]
Financial Performance
In 2024, Johnson & Johnson's revenue was $88.82 billion, an increase of 4.30% compared to the previous year's $85.16 billion. Earnings were $14.07 billion, a decrease of -59.99%.
Financial numbers in USD Financial StatementsNews
New data show TREMFYA® (guselkumab) is the only IL-23 inhibitor proven to significantly inhibit progression of joint structural damage in active psoriatic arthritis
TREMFYA ® demonstrated two and a half times greater ability to inhibit joint structural damage versus placebo in the Phase 3b APEX study More than 40% of TREMFYA®-treated patients across both dose g...
Johnson & Johnson Elects Daniel Pinto, President, JPMorganChase to its Board of Directors
Johnson & Johnson (NYSE: JNJ) announced today that Daniel Pinto, President, JPMorganChase, has been elected to its Board of Directors. This press release features multimedia. View the full release her...
Johnson & Johnson Elects Daniel Pinto, President, JPMorganChase to its Board of Directors
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) announced today that Daniel Pinto, President, JPMorganChase, has been elected to its Board of Directors. “We are thrilled to have Da...
Rep. Gilbert Ray Cisneros Has Bought Up to $410K Worth Of Johnson & Johnson Stock: Here's What You Should Know
June 6, 2025 records indicate that Representative Gilbert Ray Cisneros filed a purchase of Johnson & Johnson (NYSE: JNJ), valued between $39,025 and $410,000. According to the June filing, the transa...
Johnson & Johnson denies engaging in illegal DEI practices after group makes civil rights complaint
Johnson & Johnson denied wrongdoing after a conservative watchdog group accused the company of violating federal equal opportunity requirements.
Les Squires obituary
My friend Les Squires, who has died aged 76, was a scientific specialist in non-woven fabrics. He developed many materials and fabrics for medical, hygiene, insulation, agricultural and construction u...
Healthcare companies are hiring. Is it time to look for growth stocks in this beaten-down sector?
The recent jobs data showed that hiring in healthcare took a big jump in May, as the stock sector has stabilized a bit after years of underperformance.
Johnson & Johnson Highlights Multiple Blood Cancer Trial Data At ASCO Presentation
Johnson & Johnson (NYSE: JNJ) shared data from several cancer studies at the 2025 American Society of Clinical Oncology (ASCO) annual meeting on Tuesday. Here’s that the New Brunswick, New Jersey-bas...
Single infusion of CARVYKTI® (ciltacabtagene autoleucel) delivered lasting treatment-free remissions for at least five years in patients with relapsed or refractory multiple myeloma
New long-term CARTITUDE-1 data show one-third of patients treated with CARVYKTI ® remain progression-free CARTITUDE-4 analysis shows compelling overall survival and progression-free benefits in standa...
DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj)-based regimen shows 95 percent progression-free survival at four years in transplant-eligible, newly diagnosed patients with multiple myeloma who achieved sustained MRD negativity
More than half of patients maintained minimal residual disease (MRD) negativity (10-5) with DARZALEX FASPRO ® for 24 months or longer in the Phase 3 PERSEUS study Data from Phase 3 CEPHEUS study show...
Early results from Johnson & Johnson's trispecific antibody show promising response in heavily pretreated multiple myeloma patients
Phase 1 trial demonstrates encouraging clinical activity of investigational immunotherapy for relapsed or refractory multiple myeloma Novel investigational dual-antigen-targeting immunotherapy binds t...
Single infusion of CARVYKTI® (ciltacabtagene autoleucel) delivered lasting treatment-free remissions for at least five years in patients with relapsed or refractory multiple myeloma
New long-term CARTITUDE-1 data show one-third of patients treated with CARVYKTI ® remain progression-free CARTITUDE-4 analysis shows compelling overall survival and progression-free benefits in stand...
Johnson & Johnson's AKEEGA® (niraparib and abiraterone acetate dual-action tablet) is the first PARP inhibitor combo to show improved efficacy in patients with HRR-mutated mHSPC vs. current standard of care
Results from the Phase 3 AMPLITUDE study show the potential of niraparib and abiraterone acetate to delay cancer progression and worsening of symptoms1
Johnson & Johnson leads with first PARP inhibitor combo to improve efficacy in patients with HRR-altered mCSPC
Results from the Phase 3 AMPLITUDE study show the potential of AKEEGA® (niraparib and abiraterone acetate dual-action tablet) to delay cancer progression and worsening of symptoms Data show a nearly 5...
June's Top 10 High-Yield Stocks: Build A Path To A 10%+ Yield By 2035
My top 10 high-yield picks for June 2025 balance attractive dividend yields, strong financials, and competitive advantages to reduce risk and enhance returns. I use a rigorous four-step selection proc...
Biotech Bull Case, ABVX International Interest, JNJ & LLY Options Trades
"You cannot not believe in science," says Tsvetta Kaleynska. She sees biotech companies outperforming in 2025 despite a slow start to the year.
'No more tears': Author Gardiner Harris on J&J's controversies over the years
Gardiner Harris, ‘No More Tears' author and former New York Times correspondent, joins 'Squawk Box' to discuss the controversies and challenges facing Johnson & Johnson over the years.
'No more tears': Author Gardiner Harris on J&J's controversies over the years
Gardiner Harris, No More Tears author and former New York Times correspondent, joins 'Squawk Box' to discuss the controversies and challenges facing Johnson & Johnson over the years.
Tech stocks struggle while healthcare gains: Today's market overview
Tech stocks struggle while healthcare gains: Today's market overview The US stock market is showcasing a dynamic landscape today, characterized by struggles within the semiconductor sector and encoura...
Johnson & Johnson: Relative Stability In A Wild 2025 Stock Market
J&J CEO Joaquin Duato on cancer treatments, M&A outlook and 'most favored nation' policy
CNBC's Angelica Peebles and Johnson & Johnson chairman and CEO Joaquin Duato join 'Squawk Box' to discuss the company's 5-year multiple myeloma treatment study, the company's cancer treatments, M&A ou...
J&J CEO Joaquin Duato on cancer treatments, M&A outlook and 'most favored nation' policy
CNBCs Angelica Peebles and Johnson & Johnson chairman and CEO Joaquin Duato join 'Squawk Box' to discuss the company's 5-year multiple myeloma treatment study, the company's cancer treatments, M&A out...
Watch CNBC's full interview with Johnson & Johnson chairman and CEO Joaquin Duato
CNBCs Angelica Peebles and Johnson & Johnson chairman and CEO Joaquin Duato join 'Squawk Box' to discuss the company's 5-year multiple myeloma treatment study, the company's cancer treatments, M&A out...
Johnson & Johnson to Host Investor Conference Call on Second-Quarter Results
Johnson & Johnson (NYSE: JNJ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Wednesday, July 16th to review second-quarter results. Joaquin Duato, Chairman and Chief Executiv...
Johnson & Johnson to Host Investor Conference Call on Second-Quarter Results
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Wednesday, July 16th to review second-quarter results. Joaq...